No insider purchase over the last 90 days. The latest, by FASCI MICHAEL E, was filed 08 Feb 2018.
This page follows insider dealings at Growlife, Inc. as filed with SEC (Form 4), a company from the Food & Agriculture sector. Nothing new has been filed by managers of Growlife, Inc. in twelve months, the latest record being from 3 June 2022.
The full history, which starts in 2016, counts 12 purchases against no sales.
Elsewhere in the same market, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Applied Digital Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2021 · cache
25 of 34 declarations
GrowLife, Inc. is a U.S.-based issuer historically associated with the indoor cultivation supply chain and specialty hydroponics market. According to its SEC filings, the company is incorporated in Delaware, was founded in 2012 through a merger with SGT Merger Corporation, and is headquartered in Kirkland, Washington, in the United States. For French-speaking investors, GrowLife should be viewed as a micro-cap, niche operating company with a limited-margin, execution-sensitive profile rather than a broad consumer brand. It is referenced in the context of SEC Form 4 insider transactions and trades in the U.S. public markets, with the relevant market being the NYSE/NASDAQ universe. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001161582/000165495423007959/phot_10k.htm?utm_source=openai))
Operationally, GrowLife has focused on products and services for specialized growers, particularly hydroponics and indoor cultivation. Its historical filings describe a product set that includes indoor lighting systems, growing media and soils, propagation tools, hydroponic systems, cultivation accessories, bulbs, ballasts, reflectors, meters, timers, climate-control equipment, and organic plant nutrients. The company has sold through a nationwide network of knowledgeable representatives, regional centers, and an e-commerce channel, serving specialty grow operations across the United States and, in some periods, Canada. That distribution-led model has made GrowLife more of a specialty retailer and service provider than a scaled manufacturer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1161582/000165495420003682/phot_10k.htm?utm_source=openai))
In competitive terms, GrowLife operates in a fragmented market where customer relationships, product availability, and regulatory developments matter as much as brand strength. The company’s stated mission has been to support cultivators in the design, build-out, expansion, and maintenance of their facilities, which implies a relatively integrated offering spanning equipment sourcing and cultivation support. That positioning can be attractive in a market where operators prefer a one-stop supplier, but it also exposes the company to pricing pressure, working-capital demands, and demand volatility tied to the legal cannabis and specialty cultivation ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1161582/000165495420003682/phot_10k.htm?utm_source=openai))
Recent developments have been important for assessing risk. GrowLife’s 2023 Form 10-K indicated that the company remained headquartered in Kirkland and that a prior EZ-CLONE dispute had been settled, reducing its ownership stake to 19.6% and removing consolidation of that business. Separately, the SEC disclosed in 2025 an administrative proceeding concerning delinquent filings, followed by an order in December 2025 revoking the registration of GrowLife’s securities under Section 12(j). Taken together, these events suggest a business with a long operating history but significant reporting, governance, and going-forward visibility challenges. Investors should treat any fundamental view with caution and rely on verified SEC disclosures rather than outdated market narratives. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001161582/000165495423007959/phot_10k.htm?utm_source=openai))
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2021 | 6.2 m USD | -5.5 m USD | n.d. | 10-K |
| Dec 2020 | 7.0 m USD | -6.4 m USD | n.d. | 10-K |
| Dec 2019 | 8.2 m USD | -7.3 m USD | n.d. | 10-K |
| Dec 2018 | 4.6 m USD | -11.4 m USD | n.d. | 10-K |
| Dec 2017 | 2.5 m USD | -5.3 m USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.